SCHEMBL6355643

SCHEMBL6355643

Cc1ccc(OCc2ccccc2)c(CNC(=O)c2cccc(Cl)c2Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.54
LMNA P02545 4/20 0.54
SGMS2 Q8NHU3 1/20 0.51
KMT2A Q03164 2/20 0.49
MAPT P10636 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
PTGER1 P34995 3/20 0.48
PTGER4 P35408 2/20 0.48
PTGER3 P43115 2/20 0.48
PTGER2 P43116 2/20 0.48
MRGPRX4 Q96LA9 1/20 0.48
TMEM97 Q5BJF2 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
MT-CO2 P00403 1/20 0.46
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6356674 0.89 KMT2A (0.57) HPGDLMNASGMS2KMT2AMAPT
SCHEMBL6355280 0.88 LMNA (0.55) HPGDLMNASGMS2KMT2AMAPT
SCHEMBL6356922 0.88 LMNA (0.57) HPGDLMNASGMS2KMT2AMAPT
SCHEMBL6357846 0.87 SGMS2 (0.61) HPGDLMNASGMS2KMT2AMAPT
SCHEMBL6354502 0.84 KMT2A (0.54) HPGDLMNASGMS2KMT2AMAPT
SCHEMBL6354467 0.83 PTGER1 (0.55) HPGDSGMS2KMT2AMAPTSMN1; SMN2
SCHEMBL6361721 0.83 PTGER1 (0.58) SGMS2KMT2APTGER1
SCHEMBL6354409 0.83 NPC1 (0.56) HPGDLMNASGMS2KMT2AMAPT
SCHEMBL6360998 0.81 KMT2A (0.60) HPGDLMNASGMS2KMT2AMAPT
SCHEMBL6355252 0.80 SGMS2 (0.61) HPGDLMNASGMS2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 HPGD 586/4885LMNA 1197/4885SGMS2 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.